Hutchmed (China) Ltd on Friday said it will receive a milestone payment from Takeda Pharmaceutical Co Ltd after Taked ...
Hutchmed (China) Limited 22 November 2024 Press Release HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan ...
Hutchmed (China) Limited 20 November 2024 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee ...
Hutchmed (China) Limited 06 November 2024 Press Release HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and...
Hutchmed (China) Ltd on Thursday said it will receive a USD20 million payment from its partner Takeda Pharmaceutical ...
Hutchmed (China) Limited 31 October 2024 Press Release HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million...
Hutchmed (China) Limited 31 October 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ – Thursday, October 31, 2024:...
Hutchmed (China) Limited 21 October 2024 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ...
Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in ...
Hutchmed (China) Limited 16 October 2024 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response...
Takeda Pharmaceutical Co Ltd on Tuesday said it landed an approval for its Fruzaqla drug in Japan. The drug has bee ...
Hutchmed (China) Limited 24 September 2024 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Approval...
Hutchmed (China) Limited 09 September 2024 Press Release HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the...
Hutchmed (China) Ltd announced on Friday that it has voluntarily withdrawn its supplemental new drug application for ...
Hutchmed (China) Limited 30 August 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ - Friday, August 30, 2024:...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads